Moreover, to better understand the direction of the biomarker changes obtained at baseline, associations between the measured CSF biomarkers of AD pathology (tau proteins and Aβ42), cerebral glucose uptake and cognitive performance were analysed. The gene discussed is MAPT; the disease is Alzheimer disease.